Concordance between BCR-ABL mutational status before treatment and at relapse
| Mutational status at study start . | Mutational status at relapse . | No. of patients . |
|---|---|---|
| MUT | MUT | 10 |
| WT | WT | 3 |
| WT | MUT | 6 |
| MUT | MUT (other#) | 1 |
| MUT | WT | 0 |
| Mutational status at study start . | Mutational status at relapse . | No. of patients . |
|---|---|---|
| MUT | MUT | 10 |
| WT | WT | 3 |
| WT | MUT | 6 |
| MUT | MUT (other#) | 1 |
| MUT | WT | 0 |
The degree of concordance between BCR-ABL KD mutations identified at the start of treatment and at relapse was determined by comparing the results of D-HPLC analysis of initial samples with the results of D-HPLC analysis and direct sequencing of samples collected at relapse. Paired samples were available from 20 patients.
WT denotes unmutated BCR-ABL; MUT indicates the presence of any type of KD mutation. MUT (other#) denotes a switch of mutation type from a P-loop mutation at onset to an activation loop mutation at relapse.